Spyre Therapeutics Files DEF 14A for Executive Compensation
Ticker: SYRE · Form: DEF 14A · Filed: Apr 14, 2025 · CIK: 1636282
| Field | Detail |
|---|---|
| Company | Spyre Therapeutics, Inc. (SYRE) |
| Form Type | DEF 14A |
| Filed Date | Apr 14, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, proxy-statement, governance
TL;DR
Spyre Therapeutics DEF 14A out: exec comp details for FY24. Check it.
AI Summary
Spyre Therapeutics, Inc. filed a DEF 14A on April 14, 2025, detailing executive compensation and board member information. The filing covers the fiscal year ending December 31, 2024, and includes details on individuals such as Cameron Turtle and Scott Burrows. Spyre Therapeutics, formerly Aeglea BioTherapeutics, Inc., is based in Waltham, MA.
Why It Matters
This filing provides transparency into the compensation packages of Spyre Therapeutics' top executives and board members, which can influence investor decisions and company governance.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of executive compensation and board information, not indicating immediate financial risk.
Key Players & Entities
- Spyre Therapeutics, Inc. (company) — Filer
- Aeglea BioTherapeutics, Inc. (company) — Former Company Name
- Cameron Turtle (person) — Executive/Board Member
- Scott Burrows (person) — Executive/Board Member
- Jeffrey M. Goldberg (person) — Executive/Board Member
- Jonathan Alspaugh (person) — Executive/Board Member
- Dr. Anthony Quinn (person) — Executive/Board Member
- Jim Kastenmayer (person) — Executive/Board Member
FAQ
What is the primary purpose of this DEF 14A filing for Spyre Therapeutics, Inc.?
The primary purpose is to provide information regarding the solicitation of proxies for the company's annual meeting of stockholders, including details on executive compensation, board of directors, and other corporate governance matters.
When was Spyre Therapeutics, Inc. formerly known as?
Spyre Therapeutics, Inc. was formerly known as Aeglea BioTherapeutics, Inc., with a date of name change on March 11, 2015.
What is the fiscal year end for Spyre Therapeutics, Inc. as stated in the filing?
The fiscal year end for Spyre Therapeutics, Inc. is December 31.
Which individuals are listed as members in relation to compensation tables for the fiscal year 2024?
Cameron Turtle and Scott Burrows are listed as members in relation to compensation tables for the fiscal year 2024.
What is the business address of Spyre Therapeutics, Inc.?
The business address of Spyre Therapeutics, Inc. is 221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 14, 2025 by Cameron Turtle regarding Spyre Therapeutics, Inc. (SYRE).